Pérez-García Rafael, Jaldo María Teresa, Puerta Marta, Ortega Mayra, Corchete Elena, de Sequera Patricia, Martín-Navarro Juan Antonio, Albalate Marta, Alcázar Roberto
Servicio de Nefrología, Hospital Universitario Infanta Leonor, Madrid, España.
Servicio de Nefrología, Hospital Universitario Infanta Leonor, Madrid, España.
Nefrologia (Engl Ed). 2020 Sep-Oct;40(5):552-562. doi: 10.1016/j.nefro.2020.04.013. Epub 2020 Jul 7.
Hypomagnesaemia in haemodialysis (HD) is associated with increased mortality risk: its relationship with dialysis fluid (DF).
Low concentrations of magnesium (Mg) in blood have been linked to the development of diabetes, hypertension, arrhythmias, vascular calcifications and an increased risk of death in the general population and in haemodialysis patients. The composition of the dialysis fluid in terms of its magnesium concentration is one of the main determinants of magnesium in haemodialysis patients.
To study magnesium concentrations in haemodialysis patients, their predictive mortality rate and what factors are associated with hypomagnesaemia and mortality in haemodialysis.
Retrospective study of a cohort of prevalent haemodialysis patients followed up for two years. Serum magnesium was measured every six months. The analysis used the initial and average magnesium values for each patient, comparing patients with magnesium below the mean (2.1mg/dl) with those with magnesium above the mean. During the follow-up, three types of dialysis fluid were used: type 1, magnesium 0.5 mmol/l; type 3, magnesium 0.37 mmol/l (both with acetate); and type 2, magnesium 0.5 mmol/l with citrate.
We included 137 haemodialysis patients in the study, of which 72 were male and 65 were female, with a mean age of 67 (15) [26-95] years old. Of this group, 57 patients were diabetic, 70 were on online haemodiafiltration (OL-HDF) and 67 were on high-flow haemodialysis (HF-HD). The mean magnesium of the 93 patients with dialysis fluid type 1 was 2.18 (0.37) mg/dl. In the 27 patients with dialysis fluid type 3 it was 2.02 (0.42) mg/dl. And in the 17 with dialysis fluid type 2 it was 1.84 (0.24) mg/dl (p=.01). There was a pronounced direct relationship between Mg and P and albumin. After a mean follow-up of 16.6 (8.9) [3-24] months, 77 remained active, 24 had died and 36 had been transplanted or transferred. Patients with magnesium above than 2.1mg/dl had a longer survival (p=.008). The survival of patients with the three types of dialysis fluid did not differ significantly (Log-Rank, p=.424). Corrected for blood magnesium, patients with dialysis fluid with citrate have better survival (p=.009). The COX regression analysis shows how age, serum albumin, magnesium, dialysis technique and type of dialysis fluid have an independent predictive mortality rate.
Low serum magnesium levels have a greater association with an increased risk of mortality compared to high levels. The type of dialysis fluid affects the magnesium concentration and the risk of death.
血液透析(HD)中的低镁血症与死亡风险增加相关:其与透析液(DF)的关系。
血液中低浓度的镁(Mg)与糖尿病、高血压、心律失常、血管钙化的发生以及普通人群和血液透析患者的死亡风险增加有关。透析液中镁浓度的组成是血液透析患者镁含量的主要决定因素之一。
研究血液透析患者的镁浓度、其预测死亡率以及与血液透析中低镁血症和死亡率相关的因素。
对一组进行了两年随访的现存血液透析患者进行回顾性研究。每六个月测量一次血清镁。分析使用了每位患者的初始和平均镁值,将镁低于平均值(2.1mg/dl)的患者与高于平均值的患者进行比较。在随访期间,使用了三种类型的透析液:1型,镁0.5mmol/l;3型,镁0.37mmol/l(均含醋酸盐);2型,镁0.5mmol/l含柠檬酸盐。
我们在研究中纳入了137名血液透析患者,其中72名男性和65名女性,平均年龄为67(15)[26 - 95]岁。在该组中,57名患者患有糖尿病,70名进行在线血液透析滤过(OL - HDF),67名进行高流量血液透析(HF - HD)。93名使用1型透析液的患者的平均镁含量为2.18(0.37)mg/dl。27名使用3型透析液的患者中为2.02(0.42)mg/dl。17名使用2型透析液的患者中为1.84(0.24)mg/dl(p = 0.01)。镁与磷和白蛋白之间存在明显的直接关系。平均随访16.6(8.9)[3 - 24]个月后,77人仍存活,24人死亡,36人已接受移植或转院。镁高于2.1mg/dl的患者生存期更长(p = 0.008)。三种类型透析液患者的生存率无显著差异(对数秩检验,p = 0.424)。校正血镁后,使用含柠檬酸盐透析液的患者生存率更高(p = 0.009)。COX回归分析显示年龄、血清白蛋白、镁、透析技术和透析液类型如何具有独立的预测死亡率。
与高血清镁水平相比,低血清镁水平与死亡风险增加的关联更大。透析液类型影响镁浓度和死亡风险。